Volume 1 | Issue 4 | DOI: https://doi.org/10.33696/haematology.1.019
Unmasking the Master of Disguise: Defining Advancements in Diagnosis of Intravascular Large B-cell Lymphoma
- 1Carbone Cancer Center, University of Wisconsin Hospital and Clinics, Wisconsin, USA
- 2Department of Medicine, University of Wisconsin School of Medicine & Public Health, Wisconsin, USA
Matthew Brunner, Mbrunner2@uwhealth.org
Received Date: October 22, 2020
Accepted Date: December 21, 2020
Brunner M, Zurbriggen L, Chang JE. Unmasking the Master of Disguise: Defining Advancements in Diagnosis of Intravascular large B-cell Lymphoma. J Clin Haematol. 2020; 1(4):125-131.
Copyright: © 2020 Brunner M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Intravascular lymphoma, Rituximab, Circulating tumor DNA, Hemophagocytosis, Random skin biopsy
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Angioimmunoblastic T cell lymphoma (AITL) is one of the most common T-cell lymphomas, second only to peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Initially AITL was considered a non-malignant lymphadenopathy with immune hyperactivation, nowadays being classified as a PTCL.
Rituximab is a chimeric (20% rodent and 80% human) monoclonal antibody that binds to the CD20 antigen present on the cell surface and leads to depletion of mature B-cells [1,2]. It is the first approved monoclonal antibody to be used in the therapy of indolent B-cell non- Hodgkin’s lymphoma and chronic lymphocytic leukemia
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
Reduced BCR Signaling and a Metabolic Shift Accompanies Malignant Progression of Follicular Lymphoma: A Lesson from Transcriptomics
Lymphoma represents the most common form of hematological malignancy in the developed world, accounting for 3.6% of all cancers and 55.6% of all blood cancers in Europe, with non-Hodgkin lymphomas (NHL) representing 90% of cases.